Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584
Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584
Price:
41.47
CNY
-0.22%
Market Cap:
¥5B
Relative Value
The Relative Value of one
Nanjing Hicin Pharmaceutical Co Ltd
stock under the Base Case scenario is
25.74
CNY.
Compared to the current market price of 41.47 CNY,
Nanjing Hicin Pharmaceutical Co Ltd
is
Overvalued by 38%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
25.74
CNY
Overvaluation 38%
Multiples Across Competitors
Competitors Multiples
Nanjing Hicin Pharmaceutical Co Ltd Competitors
Nanjing Hicin Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584
|
5B CNY | 8.1 | 111.1 | 99.8 | 99.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
924.3B USD | 14.2 | 44.8 | 30.2 | 32.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.3B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.3B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
240.6B CHF | 5.5 | 22.1 | 13.7 | 17.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.1B GBP | 5.3 | 30.2 | 16.7 | 23.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.9B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.5 | 17.3 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
